Nuvectis Pharma, Inc. (NVCT)
20.22
-1.41
(-6.52%)
USD |
NASDAQ |
Sep 25, 16:00
20.30
+0.08
(+0.40%)
Pre-Market: 19:59
Nuvectis Pharma Total Liabilities (Quarterly) : 13.29M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.29M |
| March 31, 2026 | 11.18M |
| December 31, 2025 | 13.30M |
| September 30, 2025 | 11.58M |
| June 30, 2025 | 10.14M |
| March 31, 2025 | 9.194M |
| December 31, 2024 | 8.894M |
| September 30, 2024 | 6.316M |
| June 30, 2024 | 5.77M |
| March 31, 2024 | 5.692M |
| December 31, 2023 | 6.984M |
| Date | Value |
|---|---|
| September 30, 2023 | 5.576M |
| June 30, 2023 | 4.609M |
| March 31, 2023 | 3.934M |
| December 31, 2022 | 6.186M |
| September 30, 2022 | 4.492M |
| June 30, 2022 | 2.738M |
| March 31, 2022 | 3.059M |
| December 31, 2021 | 2.419M |
| September 30, 2021 | 0.495M |
| June 30, 2021 | 0.389M |
| March 31, 2021 | 0.033M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Decoy Therapeutics, Inc. | 4.680M |
| Opus Genetics, Inc. | 105.95M |
| Faeth Therapeutics, Inc. | 9.581M |
| Unicycive Therapeutics, Inc. | 18.76M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 22.38M |
| Shareholders Equity (Quarterly) | 9.082M |
| Current Ratio | 1.683 |